Photodynamic therapy: current role in the treatment of chorioretinal conditions
| Autor: | D K Newman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Porphyrins genetic structures medicine.medical_treatment Treatment outcome Glaucoma Choroidal haemangioma Photodynamic therapy Ophthalmic pathology Neuro-ophthalmology 03 medical and health sciences 0302 clinical medicine Retinal Diseases Ophthalmology medicine Humans Peripheral Vascular Diseases Photosensitizing Agents business.industry Lasers Verteporfin Choroid Diseases Macular degeneration medicine.disease eye diseases Cambridge Ophthalmological Symposium 030104 developmental biology Photochemotherapy 030221 ophthalmology & optometry sense organs business medicine.drug |
| Popis: | Verteporfin photodynamic therapy (vPDT) is a selective vaso-occlusive treatment that targets choroidal vascular abnormalities. It was initially developed to treat neovascular age-related macular degeneration using the 'standard' vPDT protocol (verteporfin 6 mg/m(2), vPDT laser fluence 50 J/cm(2)). vPDT therapy has subsequently evolved as an important treatment modality for a range of other chorioretinal conditions including choroidal haemangioma, central serous chorioretinopathy, polypoidal choroidal vasculopathy, and peripapillary choroidal neovascularisation. Various 'safety-enhanced' vPDT protocols have been devised to optimise treatment outcomes, typically using reduced dose verteporfin (verteporfin 3 mg/m(2)) or reduced fluence vPDT (vPDT laser fluence 25 J/cm(2)). This paper reviews the current role of vPDT therapy in the treatment of chorioretinal conditions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|